Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Session OT3

Poster Session OT3 
  Ongoing Clinical Trials 3: Chemotherapy
OT3-1-01 A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction chemotherapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214)
Yoshinami T, Nakayama T, Ikeda M, Iwamoto M, Komoike Y, Takashima T, Tsurutami J, Yoshidome K, Morita S, Masuda N. Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; Fkuyama City Hospital, Fukuyama, Hirosima, Japan; Osaka Medical College, Osaka, Japan; Kinki University Faculty of Medicine, Osaka, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; Osaka Police Hospital, Osaka, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; NHO Osaka National Hospital, Osaka, Japan.
OT3-1-02 The SNAP trial: Schedules of nab-paclitaxel in metastatic breast cancer, International breast cancer study group (IBCSG 42-12) and breast International group (BIG 2-12)
Gennari A, Jerusalem G, Maibach R. International Breast Cancer Study Group, Bern, Switzerland.
OT3-1-03 DIRECT: A phase II/III randomized trial with dietary restriction as an adjunct to neoadjuvant chemotherapy for HER2-negative breast cancer
de Groot S, Vreeswijk MPG, Smit VTHBM, Heijns JB, Imholz ALT, Kessels LW, Jager A, Los M, Weijl NI, Smorenburg CH, Portielje JEA, Liefers GJ, van de Velde CJH, Meershoek EM, van Leeuwen E, Fischer MJ, Kaptein AA, Putter H, Longo V, Nortier HWR, van der Hoeven KJM, Pijl H, Kroep JR. Leiden University Medical Center, Leiden, Netherlands; Amphia Hospital, Breda, Netherlands; Deventer Hospital, Deventer, Netherlands; Erasmus Medical Center, Rotterdam, Netherlands; St. Antonius Hospital, Nieuwegein, Netherlands; Bronovo Hospital, Den Haag, Netherlands; Medical Center Alkmaar, Alkmaar, Netherlands; Haga Hospital, Den Haag, Netherlands; Boog Study Center.
OT3-1-04 Phase III study evaluating the role of zoledronic acid in the adjuvant treatment of triple-negative breast cancer
Fan Y, Xu BH, Li Q, Zhang P, Yuan P. Cancer Hospital & Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
OT3-1-05 Phase II randomized study of bevacizumab combined with chemotherapy vs chemotherapy alone in the first-line treatment of triple negative breast cancer or high Ki67 HER2 negative, breast cancer
Fan Y, Xu BH, Ma F, Wang JY, Luo Y. Cancer Hospital&Institute, Chinese Academy of Medical Sciences, Beijing, China.
OT3-1-06 CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC)
Barrios CE, Lluch A, Ruiz-Borrego M, Bines J, Torrecillas L, Carrasco E, Segalla JGM, Ruiz A, Garcia-Saenz JA, Torres R, De la Haba-Rodriguez J, Garcia-Martinez E, Morales S, Gomez H, Salvador-Bofill J, Hernando A, Martin M. PUCRS School of Medicine, Porto Alegre, Brazil; Hospital Clinico Universitario, Valencia, Spain; Hospital Universitario Virgen del Rocio, Sevilla, Spain; Instituto Nacional do Cancer, Rio de Janeiro, Brazil; 20 Noviembre ISSSTE Medical Center, Mexico City, Mexico; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Hospital Amaral Carvalho, Jahu, Brazil; Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Clinico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Instituto Maimonides de Investigacion Biomedica de Cordoba. Hospital Universitario Reina Sofia, Cordoba, Spain; Hospital Morales Meseguer, Murcia, Spain; Hospital Arnau de Vilanova, Lleida, Spain; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Hospital Valme, Sevilla, Spain; Instituto de Investigacion Sanitaria Hospital Gregorio Marañon, Universidad Complutense, Madrid, Spain.
OT3-1-07 Clinical performance, efficacy and safety of the DigniCap™ system, a scalp hypothermia system, in preventing chemotherapy induced alopecia (CIA) in patients with early stage breast cancer (ESBC)
Rugo HS, Serrurier KM, Moore A, Hurvitz S, Klein P, Cigler T, D'Agostino RB, Melin SA. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Weill Cornell Medical Center, New York, NY; University of California Los Angeles, Santa Monica, CA; Beth Israel Comprehensive Cancer Center, New York, NY; Wake Forest Baptist Medical Center, Winston-Salem, NC.
OT3-1-08 The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
Park IH, Lee KS, Im S-A, Jung KH, Park KH, Im Y-H, Lee S, Kim YJ, Kim H-J, Lee S, Lee MH, Kim T-Y, Lee K-H, Kim S-B, Ahn J-H, Nam B-H, Ro J. National Cancer Center, Korea; Seoul National University Hospital, Seoul National University College of Medicine; Asan Medical Center, University of Ulsan College of Medicine; Korea University Anam Hospital; Samsung Medical Center, Sungkyunkwan University School of Medicine; Yonsei University College of Medicine; Seoul National University Bundang Hospital, Seoul National University College of Medicine; Chung-Ang University College of Medicine; Dong-A University College of Medicine; Inha University College of Medicine.
OT3-1-09 Acupuncture to prevent chemotherapy dose reduction due to chemotherapy-induced peripheral neuropathy in breast cancer patients
Bao T, Goloubeva O, Kirk R, Primrose J, Tait N, Lewis J, Pelser C, Medeiros M, Kane D, Porter N, Gilmore S, Bellavance E, Kesmodel S, Chumsri S, Feigenberg S, Tkaczuk K. University of Maryland Greenebaum Cancer Center, Baltimore, MD; University of Maryland Peripheral Neuropathy Center, Baltimore, MD.
OT3-1-10 ASTER 70s (UNICANCER phase III trial): Is personalized adjuvant treatment for women over 70 with luminal breast cancer the way to go?
Dubot C, Bourbouloux E, Tazi Y, Cure H, Ferrero J-M, Romieu G, Rigal O, Allouache D, Abadie-Lacourtoisie S, Kirscher S, Ladoire S, Malaurie E, Blot E, Rollot F, Terret C, Baffert S, Lacroix-Triki M, Falandry C, Poggionovo C, Peyro Saint Paul HP, Orsini C, Latouche A, Bonnetain F, Girre V, Brain E. Hôpital René Huguenin / Institut Curie, Saint-Cloud, France; ICO - Centre René Gauducheau, Nantes, France; Institut Gustave Roussy, Villejuif, France; Institut Jean Godinot, Reims, France; Centre Antoine-Lacassagne, Nice, France; Institut Régional du Cancer Montpellier/Val d'Aurelle - Paul Lamarque, Montpellier, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Institut de Cancérologie de L'Ouest -site Paul Papin, Angers, France; Institut Sainte Catherine, Avignon, France; Centre Georges-François Leclerc, Dijon, France; CHI de Créteil, Creteil, France; CH Bretagne Atlantique, Vannes, France; Centre Saint-Yves, Vannes, France; Institut Curie - Hôpital Claudius Regaud, Paris, France; Centre Léon Bérard, Lyon, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier Lyon Sud, Lyon, France; Qiagen Marseille SA, Marseille, France; UNICANCER, Paris, France; CNAM, Paris, France; CHU Besançon, Besancon, France; CHD de Vendée, La Roche sur Yon, France.
OT3-1-11 tnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer
Yardley DA, Brufsky A, Conte P, Cortes J, Glück S, Nabholtz J-MA, O'Shaughnessy J, Li L, Barton D, Fandi A, Harbeck N. Sarah Canon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Padova, Padova, Italy; University Hospital Vall d'Hebron, Barcelona, Spain; University of Miami, Miami, FL; Centre de Lutte Contre le Cancer d'Auvergne, Clermont Ferrand, France; US Oncology, Dallas, TX; Celgene Corporation, Summit, NJ; Breast Center, University of Munich, Munich, Germany.
  Ongoing Clinical Trials 3: Endocrine Therapy
OT3-2-01 A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer
Yardley DA, Awada A, Cortes J, Burris HA, Peterson A, Bhattacharya S, Gianni L, Miller K, Winer E. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, Nashville, TN; Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; University Hospital of Vall Hebrón, Barcelona, Spain; Medivation Inc, San Francisco, CA; Hospital San Raffaele, Milan, Italy; Indiana University Simon Cancer Center, Indianapolis, IN; Dana Farber Cancer Institute, Boston, MA.
OT3-2-02 PreOperative window of endocrine therapy provides information to increase compliance: POWER PIINC: A feasibility study
Neumayer L, Mooney K, Factor R, Salama M, Cohen A, Serpico V, Fletcher D, Bernard P, Nelson E, McGreevy J. Huntsman Cancer Institute, Salt Lake City, UT.
OT3-2-03 An efficacy and safety trial of preoperative chemo-endocrine therapy in luminal B (HER2-negative) breast cancer: A prospective multi-institutional study
Matsunuma R, Ogura H, Ide Y, Hosokawa Y, Taki Y, Yoshida M, Tokunaga Y, Koizumi K, Sato T, Hozumi Y, Mori H, Miyamoto Y, Watanabe T, Shiiya N. Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan.
OT3-2-04 Prospective multicenter study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial
Van Asten K, Dieudonné A-S, Lintermans A, Blomme C, Brouckaert O, Lambrechts D, Wildiers H, Christiaens M-R, Timmerman D, Van Calster B, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Zaman K, Dezentjé V, Neven P. KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium.
OT3-2-05 Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer
Lin NU, Whitesell L, Gelman R, Mayer E, Krop IE, Santagata S, Lowe A, Proia D, Farooq S, Brown M, Iannone M, Lindquist S, Winer EP. Dana-Farber Cancer Institute, Boston, MA; Whitehead Institute, Cambridge, MA; Brigham & Women's Hospital, Boston, MA; Synta Pharmaceuticals.
OT3-2-06 TREND: A randomized phase II clinical trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine responsive breast cancer (IBCSG 41-13)
Dellapasqua S, Colleoni M, Maibach R. International Breast Cancer Study Group, Bern, Switzerland.
OT3-2-07 Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
Mayer IA, Bardia A, Dickler MN, Manning HC, Mahmood U, Ulaner GA, Hager JH, Rix P, Zack N, Maneval EC, Chen I, Baselga J, Arteaga CL. Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN; Massachusetts General Hospital, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Aragon Pharmaceuticals, San Diego, CA.
OT3-2-08 A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer
Traina TA, O'Shaughnessy J, Kelly C, Schwartzberg L, Gucalp A, Peterson A, Bhattacharya S, Trudeau M, Hudis CA, Schmid P. Memorial Sloan-Kettering Cancer Center, New York, NY; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; Mater Misericordiae University Hospital, Dublin, Ireland; The West Clinic, Memphis, TN; Medivation Inc, San Francisco, CA; Sunnybrook Health Sciences Center, Toronto, Canada; Brighton and Sussex Medical School, Brighton, United Kingdom.
OT3-2-09 FALCON: A randomised, double-blind, multicentre, phase III study comparing fulvestrant 500 mg with anastrozole 1 mg for postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy
Ellis MJ, Prahladan M, Green NL, Mari E, Robertson JFR. Washington University School of Medicine, St. Louis, MO; AstraZeneca UK Limited, Macclesfield, United Kingdom; Quintiles, Milan, Italy; University of Nottingham, Derby, United Kingdom.
OT3-2-10  Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy
Turner N, André F, Loibl S, Ro J, Iwata H, Harbeck N, Glück S, Verma S, Loi S, Huang Bartlett C, Thiele A, Zhang K, Koehler M, Cristofanilli M. Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Villejuif, France; German Breast Group Forschungs GmbH, Neu-Isenburg, Germany; National Cancer Center, Goyang-si, Korea; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, München, Germany; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Sunnybrook Odette Cancer Centre, Toronto, Canada; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Pfizer Inc, New York, NY; Thomas Jefferson University, Philadelphia, PA.
OT3-2-11 A phase II study of letrozole and lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer (BC)
Chumsri S, Tait N, Shetty J, Lewis J, Medeiros M, Bao T, Goloubeva O, Singh H, Sivasailam S, Sabnis G, Kazi A, Mann D, Kesmodel S, Brodie A, Tkaczuk K. University of Maryland, Balitimore, MD; University of Maryland Oncology Associates, Glen Burnie, MD; Upper Chesapeake Hematology/Oncology, Bel Air, MD; Loyola University Maryland, Baltimore, MD.
  Ongoing Clinical Trials 3: Prevention
OT3-3-01 A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors
Gucalp A, Morris PG, Zhou XK, Giri DD, Iyengar NM, Heckman-Stoddard BM, Dunn B, Garber JE, Crew KD, Hershman DL, Nangia JR, Cook ED, Brown PH, Dannenberg AJ, Hudis CA. Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; Columbia University Medical Center, New York, NY; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Weill Cornell Medical College, New York, NY; NCI/Division of Cancer Prevention, Bethesda, MD.
OT3-3-02 Phase IIB randomized double-blind placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer: SWOG S0812
Crew KD, Lew DL, Hershman DL, Refice S, Anderson GL, Hortobagyi GN, Goodman GE, Brown PH. Columbia University, New York, NY; SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA; MD Anderson Cancer Center, Houston, TX; Swedish Medical Center Cancer Institute, Seattle, WA.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy